# Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

> **NCT00837876** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Erlotinb

## Key facts

- **NCT ID:** NCT00837876
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-04
- **Final completion:** 2012-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837876, "Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00837876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*